Close menu




June 1st, 2022 | 13:44 CEST

Rain of money for BioNTech shareholders: What are Nordex and Meta Materials doing?

  • metamaterials
  • Biotechnology
Photo credits: pixabay.com

BioNTech shareholders are in for a windfall. A dividend of EUR 2 per share is to be approved at today's Annual General Meeting. Also on the agenda is a share buyback program with a volume of up to USD 1.5 billion. In addition, analysts at Goldman Sachs have commented positively on the German biotech champion. Meta Materials shareholders are still a long way from a dividend. But the hot stock has announced exciting details about its fight against stroke. At Nordex, by contrast, supply chain problems, plant closures and cyberattacks dominate the headlines. But analysts see the light at the end of the tunnel - and rightly so?

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , NORDEX SE O.N. | DE000A0D6554 , Meta Materials Inc. | US59134N1046

Table of contents:


    Meta Materials: Detect strokes early and save lives

    According to the World Stroke Organization, stroke is the second leading cause of death globally. The global cost is estimated at more than USD 721 billion and affects more than 100 million people per year. Meta Materials Inc. wants to contribute to early detection, save lives and tap into a huge market. The developer of high-performance functional materials and nanocomponents is working on a portable, low-cost radio wave imaging scanner. It will be used in ambulances for early detection of strokes or at the bedside to monitor stroke development and recovery. The Company provided an overview of the current status at a technical conference. "The application of metamaterials in medical imaging has the potential for rapid clinical adoption by enabling higher image resolution and faster scans without ionizing radiation. Our technology is leading to the development of improved diagnostic tools," said George Palikaras, president and CEO. "META has demonstrated and published the effectiveness of metamaterial technology in both imaging and sensing. I am personally very excited to see how this technology will change people's lives."

    Meta's approach has been featured in several technical articles and was recently secured as a US patent. The radio wave tomography system described in the US patent covers a wide range of potential applications, including breast imaging for cancer; brain imaging for clots, haemorrhages and other abnormalities; and diagnosis of internal bleeding and bone fractures after trauma. Currently, the system is being further developed at Meta's new European R&D and sales headquarters in Athens. "Timely differential diagnosis of stroke is critical, as the window of opportunity for treatment to mitigate permanent damage is short," said Dr Kosmas. "With our proposed wearable system, drugs to treat ischemic stroke by dissolving blood clots could be administered while the patient is still in the ambulance. In the case of hemorrhagic stroke, preparations for surgical intervention could begin before the patient arrives at the hospital, saving critical time in a life-and-death situation, or what medical professionals call the golden hour." The Company is also active in other exciting areas with its technology. There was an overview of this during the Company's presentation at the IIF virtual investor conference.

    BioNTech: First dividend and then positive data?

    Compared to other Corona vaccine makers, such as Moderna or Novavax, BioNTech's stock has held up well this year. And for good reason: the cash and development pipeline of the German biotech leader is bulging. In the current year, BioNTech expects sales of EUR 13 to 17 billion. After the latest quarterly figures, Goldman Sachs also found words of praise. The Company performed strongly thanks to its Corona vaccine, and sales again exceeded expectations. The focus is now likely to turn to trial data on the BioNTech/Pfizer pediatric vaccine and the various Omicron-specific ones. Meanwhile, the US Food and Drug Administration has approved a fourth vaccine for people over age 50. In addition, BioNTech and partner Pfizer have received FDA approval for the third vaccination in five- to 11-year-olds. Study data for vaccination in children under five are expected next. Data for so-called multivalent vaccines are also expected in the coming weeks. These are expected to be adapted to the Omicron variant and other strains of the virus. The timing could be right: Within two weeks, case numbers in the US have increased by nearly 60%. Europe is also preparing for a wave in the fall. At the same time, European approval of competitor Valneva's vaccine remains a long time coming.

    And thanks to the full cash register, BioNTech can, of course, conduct research on further potential blockbusters. In the area of cancer treatment alone, 16 product candidates are in clinical trials, 5 of which are already in the second phase. The biotech company expects data on preparations against infectious diseases such as malaria and tuberculosis, and in the field of oncology, in the second half of the year. If these are positive, the share price should gain new momentum. The price target from Goldman Sachs is USD 255. Currently, the BioNTech share is trading at around USD 167.

    Nordex: Little reason for hope

    Shareholders of Nordex have little to cheer about. Although wind power is an essential part of renewable energies, there is no sign of sustained positive business performance or share price development at Nordex. The Nordex share is currently trading at its 2003 level, with repeated sharp upward and downward breakouts. The latest forecast adjustment fits into the picture. The wind turbine manufacturer is expected to close the current year with a loss. Jefferies sees the wind turbine manufacturer's new targets as disappointing, even though the mood in the industry has suffered recently from similarly bad news from competitors. However, the bottom should have been reached, and the geopolitical headwinds should be receding. As a result, analysts recommend Nordex stock as a buy with a price target of EUR 16. Whether things will be better for Nordex in the future remains to be seen. Big competitors, supply chain problems and cyberattacks give little cause for hope. The fact that Nordex will no longer produce rotor blades in the future and will therefore close the plant in Rostock also does not speak for a growth company. The stock is currently trading at around EUR 11.


    The share buyback, dividend and positive study data should give the BioNTech share new momentum. Something exciting also seems to be emerging at Meta Materials. In contrast, Nordex is struggling with numerous challenges.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Nico Popp on November 30th, 2022 | 13:33 CET

    Advances in the fight against cancer: Arcus Biosciences, Gilead Sciences, Defence Therapeutics, BioNTech

    • Biotechnology
    • Covid19
    • Cancer

    Research studies from 2020 show that 72% of Germans fear cancer. However, very few people want to admit to these fears. But precisely because the subject is a big taboo, it is worth looking at the latest achievements in research. Many companies worldwide have long been fighting the epidemic - and making astonishing progress. Just recently, a US biotech announced encouraging study results. Other companies have yet to launch promising studies. We provide an overview and outline opportunities from an investor's perspective.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Fabian Lorenz on November 24th, 2022 | 12:40 CET

    New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check

    • Mining
    • Commodities
    • Biotechnology
    • chemicals

    As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.

    Read